Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neuropsychopharmacology
2014 Mar 01;394:783-91. doi: 10.1038/npp.2013.264.
Show Gene links
Show Anatomy links
Acamprosate produces its anti-relapse effects via calcium.
Spanagel R, Vengeliene V, Jandeleit B, Fischer WN, Grindstaff K, Zhang X, Gallop MA, Krstew EV, Lawrence AJ, Kiefer F.
???displayArticle.abstract???
Alcoholism is one of the most prevalent neuropsychiatric diseases, having an enormous health and socioeconomic impact. Along with a few other medications, acamprosate (Campral-calcium-bis (N-acetylhomotaurinate)) is clinically used in many countries for relapse prevention. Although there is accumulated evidence suggesting that acamprosate interferes with the glutamate system, the molecular mode of action still remains undefined. Here we show that acamprosate does not interact with proposed glutamate receptor mechanisms. In particular, acamprosate does not interact with NMDA receptors or metabotropic glutamate receptor group I. In three different preclinical animal models of either excessive alcohol drinking, alcohol-seeking, or relapse-like drinking behavior, we demonstrate that N-acetylhomotaurinate by itself is not an active psychotropic molecule. Hence, the sodium salt of N-acetylhomotaurinate (i) is ineffective in alcohol-preferring rats to reduce operant responding for ethanol, (ii) is ineffective in alcohol-seeking rats in a cue-induced reinstatement paradigm, (iii) and is ineffective in rats with an alcohol deprivation effect. Surprisingly, calcium salts produce acamprosate-like effects in all three animal models. We conclude that calcium is the active moiety of acamprosate. Indeed, when translating these findings to the human situation, we found that patients with high plasma calcium levels due to acamprosate treatment showed better primary efficacy parameters such as time to relapse and cumulative abstinence. We conclude that N-acetylhomotaurinate is a biologically inactive molecule and that the effects of acamprosate described in more than 450 published original investigations and clinical trials and 1.5 million treated patients can possibly be attributed to calcium.
Bachteler,
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
2005, Pubmed
Bachteler,
The effects of acamprosate and neramexane on cue-induced reinstatement of ethanol-seeking behavior in rat.
2005,
Pubmed Bell,
The alcohol-preferring P rat and animal models of excessive alcohol drinking.
2006,
Pubmed Boismare,
A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved?
1984,
Pubmed Chabenat,
Physicochemical, pharmacological and pharmacokinetic study of a new GABAergic compound, calcium acetylhomotaurinate.
1988,
Pubmed Chau,
Glycine receptors in the nucleus accumbens involved in the ethanol intake-reducing effect of acamprosate.
2010,
Pubmed Chau,
Glycine receptors involved in acamprosate's modulation of accumbal dopamine levels: an in vivo microdialysis study.
2010,
Pubmed Cowen,
The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.
2005,
Pubmed De Witte,
Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.
2005,
Pubmed Emsley,
Trace element levels in drinking water and cognitive function among elderly Chinese.
2000,
Pubmed Erickson,
Ethanol: modifications of acute intoxication by divalent cations.
1978,
Pubmed Harris,
Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors.
2002,
Pubmed Heilig,
Acamprosate: an alcoholism treatment that may not be what we thought.
2014,
Pubmed Heyser,
Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.
1998,
Pubmed Hopf,
Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats.
2011,
Pubmed Kiefer,
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
2003,
Pubmed Kosinski,
Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: striatum and globus pallidus.
1998,
Pubmed Lidö,
The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598.
2012,
Pubmed Litten,
Medications development to treat alcohol dependence: a vision for the next decade.
2012,
Pubmed Lynch,
Possible association of alcohol tolerance with increased synaptic Ca2+ sensitivity.
,
Pubmed Madamba,
Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro.
1996,
Pubmed Mann,
Acamprosate: recent findings and future research directions.
2008,
Pubmed Mann,
Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
2013,
Pubmed Mann,
Does Acamprosate Really Produce its Anti-Relapse Effects via Calcium? No Support from the PREDICT Study in Human Alcoholics.
2016,
Pubmed Mark,
Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty.
2009,
Pubmed Mason,
Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence.
2010,
Pubmed Mulholland,
Small conductance calcium-activated potassium type 2 channels regulate alcohol-associated plasticity of glutamatergic synapses.
2011,
Pubmed O'BRIEN,
INTENSIVE CALCIUM THERAPY AS AN INITIAL APPROACH TO THE PSYCHOTHERAPEUTIC RELATIONSHIP IN THE REHABILITATION OF THE COMPULSIVE DRINKER.
1964,
Pubmed O'BRIEN,
Experimental evidence in the treatment of alcoholism by intensive calcium therapy.
1952,
Pubmed Rammes,
The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.
2001,
Pubmed
,
Xenbase Rehm,
Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders.
2009,
Pubmed Reilly,
Effects of acamprosate on neuronal receptors and ion channels expressed in Xenopus oocytes.
2008,
Pubmed
,
Xenbase Rösner,
Acamprosate for alcohol dependence.
2010,
Pubmed Sanchis-Segura,
Behavioural assessment of drug reinforcement and addictive features in rodents: an overview.
2006,
Pubmed Scherzer,
Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: hippocampus and cortex.
1998,
Pubmed Shaham,
The reinstatement model of drug relapse: history, methodology and major findings.
2003,
Pubmed Spanagel,
Alcoholism: a systems approach from molecular physiology to addictive behavior.
2009,
Pubmed Spanagel,
Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat.
1996,
Pubmed Spanagel,
Acamprosate and alcohol: I. Effects on alcohol intake following alcohol deprivation in the rat.
1996,
Pubmed Spanagel,
New pharmacological treatment strategies for relapse prevention.
2013,
Pubmed Spanagel,
An integrated genome research network for studying the genetics of alcohol addiction.
2010,
Pubmed Spanagel,
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption.
2005,
Pubmed Spanagel,
Drugs for relapse prevention of alcoholism: ten years of progress.
2008,
Pubmed Spanagel,
Reply to: Does acamprosate really produce its anti-relapse effects via calcium? No support from the PREDICT study in human alcoholics.
2016,
Pubmed Stutzmann,
The pathogenesis of Alzheimers disease is it a lifelong "calciumopathy"?
2007,
Pubmed Tsai,
The glutamatergic basis of human alcoholism.
1995,
Pubmed Umhau,
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.
2010,
Pubmed Umhau,
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.
2011,
Pubmed Vengeliene,
Compulsive alcohol drinking in rodents.
2009,
Pubmed Zeise,
Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors.
1993,
Pubmed
